N/A N=11 Audiovestibular Function in Infratentorial Superficial Siderosis
Siderosis · Neurological Disorder · Rare Diseases
Primary: Hearing Evaluation - Pure Tone Audiometry — 57.3 decibel hearing level
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=73 Suction Cervical Stabilizer Compared to Standard Tenaculum for Intrauterine Procedures
Intrauterine Device (IUD) · Abnormal Uterine Bleeding
Primary: Patient-perceived Pain — 3; 4 score on a scale — p=0.21
Phase 1 N=3 18F-AV-1451 High Resolution Autopsy Study
Alzheimer's Disease
Primary: Relationship of Flortaucipir Scan and Pathology - Whole Cortical Composite Region — 0.429 Correlation coefficient — p=<0.001
N/A N=15 BEAST: A Pilot Trial
Anxiety Sensitivity · Functional Impairment
Primary: Mean Change in Anxiety Sensitivity — -11.15 score on a scale
Phase 2 N=25 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction
Polycystic Ovary Syndrome
Primary: Aim 1: HCG-stimulated Testosterone Area Under the Curve — 4458; 7775 Nonograms*Hour per Deciliter (ng*hr/dL) — p=<0.004
Phase 2 N=17 Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Advanced Malignant Solid Neoplasm · Cholangiocarcinoma · Metastatic Malignant Solid Neoplasm
Primary: Overall Response Rate (ORR) — 13.3 percentage of participants
N/A N=58 Speech, Linguistic and Acoustic Markers in Parkinson's Disease
Parkinson Disease · Cognitive Impairment, Mild · Speech
Primary: Mild Cognitive Impairment — 25; 0; 23; 9 Participants
N/A N=18 A 12-week Field Trial of the Move Physical Activity Support Program
Overweight and Obesity · Physical Inactivity
Primary: Acceptability of Move Program Components, Measured With the Acceptability of Intervention Measure (AIM) — 4.14; 5; 4.28; 5 score on a scale
Phase 2 N=8 A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
Alzheimer Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 4; 1; 8; 4 Participants
Phase 2 N=6 MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum
Primary: Progression Free Survival (PFS) — 0; 0 Participants
N/A N=60 Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney · Hypertension · Endothelial Dysfunction
Primary: Change in Clinic Systolic and Diastolic Blood Pressure From Baseline to 4 Weeks (End of Study) — -5.36; -7.65; -3.55; -2.73 mmHg
N/A N=132 Brief Intervention to Prevent Alcohol Socialization (BIPAS Alcohol)
Alcohol Drinking, Adolescent · Drinking Behavior · Drinking, Alcohol
Primary: Change in Mean Value of Parental Pro-sipping Beliefs Score — 0.13; 0.08 score on a scale
Phase 2 N=267 A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
Atherosclerotic Cardiovascular Disease
Primary: Percentage Change in Low-density Lipoprotein (LDL)-Cholesterol — -27; -41; -55; 6 Percentage change of LDL cholesterol — p=<.0001
N/A N=1,972 Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Mean Incidence Rate of Total Cardiovascular Disease (CVD) Events — 0.51; 0.76; 1.4; 1.54 Participants with event/100 Person years
N/A N=128 Clinical Trial of a Supporter-Targeted Intervention to Improve Outcomes in Recent Sexual Assault Survivors
Stress Disorders, Post-Traumatic · Helping Behavior · Help-Seeking Behavior
Primary: Survivor Satisfaction With Intervention at 1 Month Post-baseline (Self Report) — 28.37; 27.71 score on a scale